Abstract
Placenta-mediated pregnancy complications are clinically important conditions and include preeclampsia, placental abruption, intrauterine growth restriction, and late fetal loss. Pathophysiology is complex, and may be linked to prothrombotic disorders such as antiphospholipid syndrome, whose understanding is still evolving. In this narrative review, we will present the latest evidence to better understand hemostatic mechanisms of preeclampsia, as well as in women with placenta-mediated pregnancy complications and inherited thrombophilia or antiphospholipid antibodies. Using four clinical scenarios, the mixed results of preventive efforts through the use of antithrombotic drugs (aspirin, heparin) will be discussed. We will also review knowledge gaps and ongoing research.
Georg Thieme Verlag KG Stuttgart · New York.
MeSH terms
-
Abruptio Placentae / epidemiology
-
Adult
-
Antibodies, Antiphospholipid / blood
-
Anticoagulants / therapeutic use
-
Antiphospholipid Syndrome / complications
-
Antiphospholipid Syndrome / diagnosis
-
Antiphospholipid Syndrome / drug therapy
-
Aspirin / therapeutic use*
-
Female
-
Fetal Growth Retardation / epidemiology
-
Fetal Mortality / trends
-
Heparin, Low-Molecular-Weight / therapeutic use*
-
Humans
-
Placenta / pathology
-
Platelet Aggregation Inhibitors / therapeutic use
-
Pre-Eclampsia / epidemiology
-
Pre-Eclampsia / etiology
-
Pre-Eclampsia / prevention & control*
-
Pregnancy
-
Pregnancy Complications / etiology
-
Pregnancy Complications / physiopathology
-
Pregnancy Complications / prevention & control*
-
Risk Factors
-
Thrombophilia / complications
-
Thrombophilia / diagnosis
-
Thrombophilia / drug therapy
Substances
-
Antibodies, Antiphospholipid
-
Anticoagulants
-
Heparin, Low-Molecular-Weight
-
Platelet Aggregation Inhibitors
-
Aspirin
Supplementary concepts
-
Thrombophilia, hereditary